Skip to main content

Table 3 Patients characteristics

From: A critical assessment of SELDI-TOF-MS for biomarker discovery in serum and tissue of patients with an ovarian mass

  Serum (training cohort) Serum (validation cohort) Tissue
  Cancer LMP Benign Cancer LMP Benign Cancer LMP Benign
Patients 53 18 57 16 5 21 40 20 24
Age (years) 59.2 (11.4) 53.5 (10.3) 56.6 (12.4) 58.0 (14.8) 43.3 (8.0) 54.0 (14.5) 55.8 (11.7) 50.7 (10.3) 53.4 (15.3)
BMI 26.1 (5.4) 28.7 (8.0) 26.9 (6.0) 26.5 (4.5) 27.4 (5.8) 26.6 (4.1) 26.1 (4.5) 28.8 (8.0) 26.7 (5.0)
Premenopausal 10 6 22 5 5 11 13 10 9
Postmenopausal 43 12 35 11   10 27 10 15
Sample age (years) 2.5 (0.9) 2.3 (0.5) 2.5 (0.6) 0.7 (0.4) 0.6 (0.2) 1.7 (1.2) 2.5 (1.2) 2.5 (1.0) 2.7 (0.9)
CA125 kU/L 2451 63 42 5078 131 67 4117 89 26
(range) (7–14100) (6–396) (1–164) (111–67448) (56–284) (2–312) (7–67448) (6–396) (5–164)
Histological type          
Serous 38 13   13 3   32 6  
Mucinous 5 5   1 2   2 14  
Endometrioid 3    1    2   
Undifferentiated 5    1    3   
Clearcell 2       1   
Grade          
1 2       2   
2 12    3    9   
3 39    12    29   
NA     1      
Figo Stage          
I 6       6   
II 3       1   
III 36    13    27   
IV 8    3    6   
  1. Clinical and pathological characteristics of the three separate patient groups: cancer, low malignant potential (LMP) and benign tumor. The characteristics are given for the serum training, serum validation and tissue experiments. Age, body mass index (BMI) and sample age are given as a mean value with their standard deviation. In one patient differentiation grade was not available (NA).